Dutch coastal village turns to tech to find lost fishermen
In Urk, a fishing village in the northern Netherlands, the sea has long been the lifeblood for families -- but has often taken loved ones in return.
Some bodies never surfaced. Others washed ashore on German or Danish coasts and were buried in unnamed graves.
Despite the tragedy, Van den Berg -- the last of six children -- became a fisherman like his brothers, defying their mother's terror that the North Sea would claim her sons too.
"We never found his body," he told AFP in a low voice, mumbling under the brim of his hat.
But after decades of uncertainty, advances in DNA technology and artificial intelligence have given Van den Berg renewed hope.
Researchers are now able to match remains with living relatives more accurately than ever before, offering families long-awaited answers and the chance to finally mourn properly.
"Many families still gaze at the front door, hoping their loved-one will walk through it," said Teun Hakvoort, an Urk resident who serves as spokesperson for a new foundation dedicated to locating and identifying fishermen lost at sea.
"All sunken boats have been mapped. Using modern tech, we look at the weather and currents at the time of the shipwreck to estimate where the fishermen might have washed ashore," the 60-year-old said.
- Found after 47 years -
The foundation, Identiteit Gezocht (Identity Sought), aims to list all unknown graves on the coasts of the North Sea, hoping to identify remains.
The new searches have already borne fruit. A body was recently exhumed on Schiermonnikoog, a small island north of the Netherlands, and returned to the family.
"This man had been missing for 47 years. After all this time, DNA and this new method of work made it possible to discover he came from Urk," said Hakvoort.
Another Hakvoort, Frans Hakvoort, leads the foundation with the support of his two brothers in Urk, a tight-knit Protestant community where certain family names frequently reoccur.
The three men, who have all lost a relative at sea, dedicate their free time to searching for the missing.
"With AI, we search for press articles published after a body washed ashore, possibly in specific circumstances," said Frans Hakvoort, 44.
"We enter all this information into a database to see if we can establish a link. If so, we contact local authorities to see if they can exhume the body."
The Netherlands leads other North Sea countries in identifying the missing, he said, with about 90 percent of unknown bodies exhumed and all DNA profiles stored in a European database.
Given the usual fishing areas and prevailing currents, Urk fishermen are more likely to be buried on German or Danish coasts, he said.
The foundation has called on the public to help identify unknown graves in Germany and Denmark.
- Human remains -
Jan van den Berg runs his fingers over his father's name, engraved on a monument overlooking Urk beach to honour lost fishermen.
The list is long. More than 300 names -- fathers, brothers, and sons, with dates stretching back to the 18th century.
Among the names are about 30 fishermen never found. Kees Korf, missing since 1997 aged 19. Americo Martins, 47, in 2015.
A statue of a woman, her back turned to the sea, represents all these mothers and wives hoping their loved-one returns.
"My father disappeared during a storm on a freezing October night in 1954," says Van den Berg.
"One morning he left the port heading for the North Sea. He was not supposed to be gone long because I was about to be born."
His uncle, who was also aboard, later said his father was on deck when wild waves flipped the boat over.
The tragedy still haunts the family to this day.
"When they pulled the nets on deck with fish, my older brothers always feared there might be something that looked like a human," van den Berg said.
In 1976, his uncle's boat disappeared with two of his cousins, aged 15 and 17, also on board.
He was among those who found the body of Jan Jurie, the eldest, four months later.
The others were never found.
"Not a day goes by without thinking of them, all those men, and that is why I take part in the searches and give my DNA, because it remains an open wound," he said.
"I would like to have at least a small bone of my father to place in my mother's grave." And finally be able to mourn.
cvo/srg/ric/gv
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ('Biodexa' or 'the Company'), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced the filing of a Clinical Trial Application (CTA) with the European Medicines Agency (EMA) for its Serenta trial in patients with familial adenomatous polyposis (FAP), a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer. The only current treatment option is sequential resection of much of the gastrointestinal tract. A CTA is the formal regulatory submission required to obtain approval to begin a clinical trial in Europe and is similar to the Investigational New Drug (IND) application process in the United States. if approved, it would permit the Serenta trial to proceed in Europe, initially covering clinical sites in Denmark, Germany, Netherlands and Spain with Italy expected to be added in due course. Commenting, Stephen Stamp CEO and CFO of Biodexa said 'Following Fast Track Designation by the FDA, Orphan Drug designation in Europe and initiation of our first clinical site in the US, the filing of our CTA with EMA is the latest in a series of important milestones for our eRapa Phase 3 program in FAP. Congratulations to our team, our collaborators at Emtora Biosciences and our European CRO, Precision for Medicine. This would not have been possible without the support of CPRIT which has awarded $20 million in grant funding to support the program'. The Serenta trial (NCT06950385) is a randomized, double-blind, placebo-controlled Phase 3 registrational study designed to evaluate the safety and efficacy of eRapa in patients diagnosed with FAP. The first site, in the US, is now open and actively screening eligible participants. Following the 106 day approval timeline for the CTA, it is expected the European sites will begin enrolling in the fourth quarter of this year. For more information about the Serenta trial, including eligibility criteria and specific site location, please visit About FAPFamilial adenomatous polyposis is a rare, inherited disorder characterized by the development of hundreds to thousands of colorectal polyps and a near-100% lifetime risk of colorectal cancer if left untreated. There is a significant unmet need for effective, less invasive therapies for FAP patients. FAP is characterized as a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option for treating FAP patients, for whom active surveillance and surgical resection of the colon and/or rectum remain the standard of care. If untreated, FAP typically leads to cancer of the colon and/or rectum. There is a significant hereditary component to FAP with a reported prevalence of one in 5,000 to 10,000 in the US1 and one in 11,300 to 37,600 in Europe2. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using an mTOR inhibitor like eRapa to treat FAP. About eRapa eRapa is a proprietary oral formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis3.. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune®. Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035, with other pending applications potentially providing further protection beyond 2035. The Cancer Prevention and Research Institute of TexasTo date, CPRIT has awarded $2.9 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs. CPRIT has recruited 237 distinguished researchers, supported the establishment, expansion or relocation of 43 companies to Texas and generated over $5.7 billion in additional public and private investment. CPRIT funding has advanced scientific and clinical knowledge and provided 7.4 million life-saving cancer prevention and early detection services reaching Texans from all 254 counties. On November 5, 2019, Texas voters overwhelmingly approved a constitutional amendment to provide an additional $3 billion to CPRIT for a total $6 billion investment in cancer research and prevention. Learn more at 1. Tian et al., mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy, Int J Mol Sci. 2019 Feb; 20(3): 755 For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 20480 180 About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa's headquarters and R&D facility is in Cardiff, UK. For more information visit Forward-Looking StatementsCertain statements in this announcement may constitute 'forward-looking statements' within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not anticipate', or 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved.' Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Yahoo
'Massive' 1,000 Pound Shark Caught at Popular U.S. Beach
Anglers dropped bait into the Gulf of Mexico on Thursday morning, and they were met with the catch of a lifetime just a few short hours later. Trey Linder and Steve Callaway caught a huge tiger shark. The shark measured an astonishing 11 feet and 8 inches, and it weighed in at an estimated 1,000 pounds. Linder and Callaway posed for a photo with the shark before tagging it and releasing it back into the water near Pensacola, Florida. The anglers The anglers, who work with Shark and Shore, noted that it takes around three minutes to tag, take photos and release the sharks back into the water. The sharks are tagged for the National Oceanic and Atmospheric Administration, and NOAA says that the summer is usually the best time to catch sharks. Shark biologist John Carlson says that coastal sharks come closer inland in search of warmer water so they can give birth, leading to more sightings in the summer months. The anglers were taken out on a boat from Coast Guard Yakers LBSF Charters, and they were able to bring the anglers near one of the biggest catches of their careers on. the water. The Florida Museum says that tiger sharks are the most commonly caught coastal shark in the United States. They can grow up to 2,000 pounds, and to over 18 feet. Tiger sharks aren't as dangerous as great whites, but they still pose a threat to those who are in the water. Tiger sharks account for the second-most bites on humans around the world, and they can sometimes mistake humans for their natural prey like sea turtles. NOAA lists several shark species on its website, as it continues to focus conservation efforts on dwindling or nearly extinct populations. "We are committed to sustainable shark management," the organizations says about its policies regarding shark conservation. "We manage commercial and recreational shark fisheries in the Atlantic Ocean and work with three regional fishery management councils to conserve and sustainably manage sharks in the Pacific Ocean." NOAA notes that it conducts research, assesses stocks, works with U.S. fishermen and implements restrictions on shark harvests. "We have made significant progress toward ending overfishing and rebuilding overfished stocks for long-term sustainability," they said. After catching and monitoring one of the largest sharks in the Gulf, the team has certainly done more than enough in and around Pensacola. 'Massive' 1,000 Pound Shark Caught at Popular U.S. Beach first appeared on Men's Journal on Jul 13, 2025
Yahoo
3 days ago
- Yahoo
Atlantic Ocean's Nanoplastic Problem Revealed in Shocking New Study
Motes of plastic less than a micrometer across could outnumber larger fragments and particles floating through the oceans to a shocking extent, a new study has discovered. Led by a team from Utrecht University in the Netherlands, the study is based on samples taken at varying depths from 12 sites across the North Atlantic. High-resolution imaging scans and chemical filtering were used to find nanoplastics in the samples, which can be tricky to spot due to their very small size (just a fraction of the thickness of a human hair). The analysis was clear: the ocean is swimming with nanoplastics, perhaps some 27 million tonnes when extrapolated across the whole of the North Atlantic Ocean. That's almost a tenth of the entire volume of trash thrown away in the US each year. "This estimate shows that there is more plastic in the form of nanoparticles floating in this part of the ocean than there is in larger micro or macroplastics floating in the Atlantic or even all the world's oceans," says biogeochemist Helge Niemann, from Utrecht University. Related: The findings illustrate the sheer scale of the ecological problem posed by waste plastics. Polyethylene terephthalate (PET), polystyrene (PS), and polyvinyl chloride (PVC) plastics were all found, commonly used in plastic bottles, cups, and films. Some plastics were largely missing though: polyethylene and polypropylene, which are ubiquitous in the environment. The researchers think this might be because organic particles are masking their presence, or the analysis techniques in use aren't currently sensitive enough to pick these types of plastic up. Nanoplastics were found at all of the surveyed depths, but were particularly concentrated around the coasts (from rivers and runoff) and in the subtropical gyre, a place of swirling circular currents that's well known for trapping plastics which proceed to break up into ever-finer pieces. What's not clear is the precise extent to which plastics harm marine ecosystems, and in turn species that rely upon them. Including our own. Super-small nanoplastics can interact with water, sediment, and other organisms in ways larger microplastics can't. "Nanoplastic and nanoparticles are so small that the physical laws governing larger particles often no longer apply," says chemist Dušan Materić, from the Helmholtz Centre for Environmental Research in Germany. Next, the researchers want to see more ocean areas sampled, with surveys scanned for more types of plastic – something that should be possible by adapting the techniques used in this study. It's also important to look for nanoplastics at different stages of degradation, based on how long they've been in the water. Plastic pollution at this scale is going to be very difficult to eliminate, which is why the researchers are calling for more to be done to stop plastics from entering the environment in the first place. "Only a couple of years ago, there was still debate over whether nanoplastic even exists," says Materić. "Many scholars continue to believe that nanoplastics are thermodynamically unlikely to persist in nature, as their formation requires high energy." "Our findings show that, by mass, the amount of nanoplastic is comparable to what was previously found for macro and microplastic – at least in this ocean system." The research has been published in Nature. Scientists Discovered This Amazing Practical Use For Leftover Coffee Grounds Antarctica's Ocean Is Mysteriously Getting Saltier, Spelling End to Sea Ice Earth's Energy Imbalance Has Doubled in 2 Decades, Study Warns